Flores et al., demonstrated that HSC CCR2+ cells move from the bone marrow to intracranial PD-L1 resistant brain tumors (GBM and medulloblastoma), where they produce APCs like Mo-DCs that activate the CD8+ T-response against tumor cells. This evidence concerns the gene CD8A and neoplasm.